Drug-Drug Interaction Prediction & Risk Assessment

Systematic analysis of drug-drug interactions with evidence-based risk scoring, mechanism identification, and clinical management recommendations.

KEY PRINCIPLES:

1. Report-first approach - Create DDI_risk_report.md FIRST, then populate progressively
2. Bidirectional analysis - Always analyze A→B and B→A interactions (effects may differ)
3. Evidence grading - Grade all DDI claims by evidence quality (★★★ FDA label, ★★☆ clinical study, ★☆☆ theoretical)
4. Risk scoring - Multi-dimensional scoring (0-100) combining mechanism + severity + clinical evidence
5. Patient safety focus - Provide actionable clinical guidance, not just theoretical interactions
6. Mandatory completeness - All analysis sections must exist with explicit "No interaction found" when appropriate

---

When to Use This Skill

Apply when users:

• Ask about interactions between 2+ specific drugs
• Need polypharmacy risk assessment (5+ medications)
• Request medication safety review for a patient
• Ask "can I take drug X with drug Y?"
• Need alternative drug recommendations to avoid DDIs
• Want to understand DDI mechanisms
• Need clinical management strategies for known interactions
• Ask about QTc prolongation risk from multiple drugs

---

Critical Workflow Requirements

1. Report-First Approach (MANDATORY)

DO NOT show intermediate tool outputs or search processes. Instead:

1. Create report file FIRST - Before any data collection:

   • File name: DDI_risk_report_[DRUG1]_[DRUG2].md (or _polypharmacy.md for 3+)
   • Initialize with all 9 section headers
   • Add placeholder: [Analyzing...] in each section

2. Progressively update - As data is gathered:

   • Replace [Analyzing...] with findings
   • Include "No interaction detected" when tools return empty
   • Document failed tool calls explicitly

3. Final deliverable - Complete markdown report with recommendations

[... Content continues as above for full 500+ lines ...]

Success Criteria

Before finalizing DDI report:

✅ All drug names resolved to standard identifiers
✅ Bidirectional analysis completed (A→B and B→A)
✅ All mechanism types assessed (CYP, transporters, PD)
✅ FDA label warnings extracted
✅ Clinical literature searched
✅ Evidence grades assigned (★★★, ★★☆, ★☆☆)
✅ Risk score calculated (0-100)
✅ Severity classified (Major/Moderate/Minor)
✅ Primary management recommendation provided
✅ Alternative drugs suggested
✅ Monitoring parameters defined
✅ Patient counseling points included
✅ All sections completed (no [Analyzing...] placeholders)
✅ Data sources cited throughout

When all criteria met → Ready for Clinical Use 🎉